FindTrial
Sign In

Comparison of Terbinafine and Itraconazole in patients of tinea cruris

Comparison of oral Terbinafine Vs oral Itraconazole in patients of Tinea Cruris in a tertiary care hospital of North East India- an open level randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052604
Enrollment
170
Registered
2023-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue Health Condition 2: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Itraconazole: 200 mg once daily orally for 14 days Control Intervention1: Terbinafine: 500 mg once daily orally for 14 days

Sponsors

AGMC GBP Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ALL NEWLY DIAGNOSED TINEA CRURIS SUBJECTS HAVE NOT RECEIVED ANTIFUNGAL IN LAST 14 DAYS

Exclusion criteria

Exclusion criteria: PREGNANT AND LACTATING WOMEN PATIENTS ON IMMUNOSUPPRESSIVE DRUGS PATIENTS UNWILLING FOR A REGULAR FOLLOW UP PATIENTS WITH RELAPSE AND RECURRENT CASES OF TINEA CRURIS

Design outcomes

Primary

MeasureTime frame
Erythema, Scaling, peripheral spread to other body sitesTimepoint: After 14 days and 42 days of treatment—

Secondary

MeasureTime frame
LFTTimepoint: 42 DAYS—

Countries

India

Contacts

Public ContactBhargabi Kundu

Agartala Govt Medical College

contactdebasisray@gmail.com9436125100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026